.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Argus Health
Cipla
Baxter
Healthtrust
Mallinckrodt
Chubb
Citi
Express Scripts

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,977,324

« Back to Dashboard

Which drugs does patent 7,977,324 protect, and when does it expire?


Patent 7,977,324 protects OVIDE and is included in one NDA. There has been one Paragraph IV challenge on Ovide.

This patent has ten patent family members in seven countries.

Summary for Patent: 7,977,324

Title:Process for preparing malathion for pharmaceutical use
Abstract: The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate (MeOOSPO), O,S,S-trimethyl phosphorodithioate (MeOSSPO), malaoxon, isomalathion, diethyl fumarate, methyl malathion, dimethyl malathion, O,O-methyl,ethyl-S-(1,2-dicarboethoxy)ethyl-phosphorodithioate are lower than that of any other commercial preparation of malathion that may be used for pharmaceutical purposes.
Inventor(s): Gutman; Daniella (Rishon Lezion, IL), Baidussi; Wael (Hamisholash, IL)
Assignee: Taro Pharmaceuticals North America, Inc. (Cayman, KY)
Application Number:12/353,691
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Taro Pharm
OVIDE
malathion
LOTION;TOPICAL018613-001Aug 2, 1982ATRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,977,324

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,560,445Process for preparing malathion for pharmaceutical use► Subscribe
8,957,238Process for preparing malathion for pharmaceutical use► Subscribe
8,536,155Process for preparing malathion for pharmaceutical use► Subscribe
8,039,657Process for preparing malathion for pharmaceutical use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,977,324

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
BrazilPI0612686► Subscribe
Canada2612578► Subscribe
China101287374► Subscribe
China103087095► Subscribe
European Patent Office1898707► Subscribe
Israel188512► Subscribe
Japan2009500422► Subscribe
Japan2013032405► Subscribe
Japan5474347► Subscribe
World Intellectual Property Organization (WIPO)2007005988► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Deloitte
Cipla
Accenture
McKesson
Colorcon
Farmers Insurance
Novartis
Merck
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot